机译:随机开放标签期II试验5天的4. ondansetron与Ondansetron相比,单独在预防接受佐剂替斯替替莫唑胺的胶质瘤患者中预防化疗诱导的恶心呕吐(CINV)
1grid.189509.c0000000100241216Department of PharmacyDuke University HospitalDurhamUSA;
2grid.189509.c0000000100241216Department of Neurosurgery The Preston Robert Tisch Brain Tumor;
2grid.189509.c0000000100241216Department of Neurosurgery The Preston Robert Tisch Brain Tumor;
2grid.189509.c0000000100241216Department of Neurosurgery The Preston Robert Tisch Brain Tumor;
2grid.189509.c0000000100241216Department of Neurosurgery The Preston Robert Tisch Brain Tumor;
4Duke Cancer Center BiostatisticsDurhamNCUSA;
4Duke Cancer Center BiostatisticsDurhamNCUSA;
4Duke Cancer Center BiostatisticsDurhamNCUSA;
2grid.189509.c0000000100241216Department of Neurosurgery The Preston Robert Tisch Brain Tumor;
2grid.189509.c0000000100241216Department of Neurosurgery The Preston Robert Tisch Brain Tumor;
2grid.189509.c0000000100241216Department of Neurosurgery The Preston Robert Tisch Brain Tumor;
2grid.189509.c0000000100241216Department of Neurosurgery The Preston Robert Tisch Brain Tumor;
Nausea; Vomiting; Glioma; NK1-receptor antagonist;
机译:随机开放标签期II试验5天的4. ondansetron与Ondansetron相比,单独在预防接受佐剂替斯替替莫唑胺的胶质瘤患者中预防化疗诱导的恶心呕吐(CINV)
机译:恩丹西酮单独与恩丹西酮和阿瑞匹坦联合用于预防接受大剂量阿糖胞苷治疗的血液系统恶性肿瘤患者的恶心和呕吐的II期,开放标签,随机比较试验
机译:恩丹西酮单独与恩丹西酮和阿瑞匹坦联合用于预防接受大剂量阿糖胞苷治疗的血液系统恶性肿瘤患者的恶心和呕吐的II期,开放标签,随机比较试验
机译:风险适应的静脉内莫尔甘蔗用佐剂沙利度胺和地塞米松,用于新诊断的未经治疗的全身淀粉样蛋白症患者:II期试验的中期报告
机译:涉及诊断为2型糖尿病的肥胖患者的有关减肥实践的随机III期临床试验中的招募,保留和依从性报告。
机译:恩丹西酮单独与恩丹西酮和阿瑞匹坦联合用于预防接受高剂量阿糖胞苷治疗的血液系统恶性肿瘤患者的恶心和呕吐的II期开放标签随机比较试验
机译:信件引用“5天的随机开放标签期第二次试验与ondansetron相比,与ondansetron相比,单独在预防接受佐剂替斯替斯多洛族蛋白的胶质瘤患者中的化疗诱导的恶心呕吐”